Evaluating the completeness and accuracy of MedWatch data

American Journal of Therapeutics

Volumn 21, Issue 6, 2014, Pages 442-446

  Getz, Kenneth A ^a   Stergiopoulos, Stella ^a   Kaitin, Kenneth I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse event reporting; Drug safety; Pharmacovigilance; Postmarketing surveillance

Indexed keywords

DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FOOD AND DRUG ADMINISTRATION; HUMAN; POSTMARKETING SURVEILLANCE; PROCEDURES; STANDARDS; STATISTICAL BIAS; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIAS (EPIDEMIOLOGY); DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84914164807     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318262316f     Document Type: Article

References (10)

1. Kessler D. Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA. 1993;269:2765-2768.
2. FDA. Available at http://www.fda.gov/Safety/MedWatch/ucm170520.htm. Accessed July 4, 2012.
3. White G, Love L. Food and drug administration update. Clin Toxicol. 1998;36:145-149.
4. Ahmad S, Goetch R, Marks N. Spontaneous Reporting in the United States. Pharmacoepidemiology. 4th ed. Jon Wiley and Sons; 2005:135-159.
5. Scott H, Thacher-Renshaw A, Rosenbaum S, et al. Physician reporting of adverse drug reactions. JAMA. 1990; 263:1785-1788.
6. Tufts Center for the Study of Drug Development analysis of data from the Office of Drug Safety. Available at: www.fda.gov. Accessed July 4, 2012.
7. Hauben M, Horn S, Reich L. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions. Drug Safety. 2007;30:143-155.
8. Ahmad S, Kortepeter C, Brinker A, et al. Renal failure with the use of celecoxib and rofecoxib. Drug Safety. 2002;25:537-544.
9. Baker R, Pikalov A, tran Q, et al. Atypical antipsychotic drugs and diabetes mellitus in the ES food and drug administration adverse event database. Psychopharmacol Bull. 2009;42:11-31.
10. Kothany N, Diak I, Brinker A, et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol. 2011;65:546-551.